Your session is about to expire
← Back to Search
Hypofractionated Stereotactic Irradiation for Malignant Glioma
Study Summary
This trial is testing whether a combination of different immunotherapy drugs, given with a type of radiation treatment, is safe and tolerated by people with a certain type of brain tumor.
- Malignant Glioma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is Nivolumab known to cause any serious health complications?
"Nivolumab's safety is largely unproven as it is only in Phase 1 trials."
Nivolumab is frequently used to treat which type of cancer?
"Nivolumab is frequently used as a treatment for patients with unresectable melanoma. It is also used to manage squamous cell carcinoma, locally advanced nonsquamous non-small cell lung cancer, and high risk of recurrence."
What other precedent does Nivolumab have in medical research?
"1164 studies are currently being conducted for Nivolumab with 181 of those in the final stage of testing. The majority of these studies are taking place in Pittsburgh, though there are 61232 total locations running Nivolumab trials."
Share this study with friends
Copy Link
Messenger